CPT code 0269U: Gene analysis, 22-gene thrombocytopenia panel2026 Medicare lab fee · Clinical Laboratory Fee Schedule
Genomic sequence analysis of 22 genes for abnormalities associated with autosomal dominant congenital thrombocytopenia, using blood, buccal swab, or amniotic fluid.
Medicare pays $608.17 for 0269U under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.
Medicare lab fee · CLFS 2026 Q4
National CLFS amount
$608.17
In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.
- Geographic adjustment
- None
- Office vs facility
- Same
- Since 2023
- Unchanged
- CMS updates
- Quarterly
Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.
On this page 7 sections
What 0269U covers
0269U identifies genomic sequence analysis of 22 genes for abnormalities associated with autosomal dominant congenital thrombocytopenia. The associated specimen types are blood, buccal swab, and amniotic fluid. This is a condition-focused molecular laboratory analysis, distinct from a general platelet evaluation or a hematologic malignancy panel. The specimen options do not change the identity of the 22-gene analysis represented by the code.
Report 0269U for this specified analysis. Medicare pays it only through the CLFS, at one national amount across states and localities, with no geographic or office-versus-facility adjustment. The 2026 national CLFS amount is $608.17, unchanged from 2023 through 2025. The code has no physician fee schedule row and is paid only from the CLFS.
This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.
How Medicare pays 0269U
Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.
One national amount
CMS sets a single Clinical Laboratory Fee Schedule amount for 0269U. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.
No office or facility rate
Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.
Updated every quarter
CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.
Not on the physician fee schedule
The physician fee schedule doesn’t list 0269U: Medicare pays the test only from the CLFS.
0269U on the lab fee schedule since 2021
0269U · CLFS 2026 Q4 (current)
$608.17
Unchanged since Jan 1, 2023
Every change on file
- Jan 1, 2023 · CLFS 2023 Q1MAC-priced → $608.17
21 quarterly CLFS releases on file, first CLFS 2021 Q4. A code missing from a quarter wasn’t on that release.
0269U compared with similar tests
- 0268UaHUS genetic test15-gene sequence analysis$608.17
- Both are hematology genomic analyses, but 0268U is associated with atypical hemolytic uremic syndrome; 0269U is for abnormalities associated with autosomal dominant congenital thrombocytopenia.
- 81450Hematolymphoid panel5–50 genes, DNA or combined$759.53
- CPT 81450 is for genomic analysis of a hematologic malignancy or neoplasm. 0269U identifies the specified congenital thrombocytopenia analysis.
0269U billing questions
Which specimen types are associated with 0269U?
The analysis is associated with blood, buccal swab, or amniotic fluid. The specimen type does not change the identity of the specified 22-gene analysis.
How does 0269U differ from 0268U?
0269U is a 22-gene analysis for abnormalities associated with autosomal dominant congenital thrombocytopenia. 0268U is a separate hematology genomic analysis associated with atypical hemolytic uremic syndrome.
Is 0269U the same as a hematologic malignancy gene panel?
No. 0269U is for the specified congenital thrombocytopenia analysis; CPT 81450 is for genomic analysis of a hematologic malignancy or neoplasm.
How does Medicare pay 0269U?
Medicare pays it under the CLFS at one national amount, with no locality or office-versus-facility adjustment.
Does 0269U have a separately payable physician interpretation component?
The code is paid only through the CLFS and has no physician fee schedule row.
Where this amount comes from
FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.
CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027
Show the CMS file line behind this amount
Fee sheets · Coming soon
Put 0269U and the rest of your codes on one sheet
Your codes at your locality, with payer contracts beside Medicare.
Join the waitlist